Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes
- PMID: 34650195
- PMCID: PMC8668432
- DOI: 10.1038/s41440-021-00756-5
Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes
Abstract
There are limited data on the nighttime blood pressure (BP)-lowering effect of esaxerenone and its effect on N-terminal pro b-type natriuretic peptide (NT-proBNP), a predictor of cardiovascular risk, according to different dipping patterns of nocturnal BP. This was a post hoc analysis of a multicenter, open-label, long-term phase 3 study of esaxerenone, a new highly selective mineralocorticoid receptor blocker, in patients with essential hypertension. Patients were classified by dipping pattern (extreme dippers, dippers, non-dippers, risers). Mean changes in BP, changes in dipping pattern, mean NT-proBNP levels, and percentage of patients with normal NT-proBNP levels (<55 pg/mL) at baseline and Weeks 12 and 28 were evaluated. Nighttime systolic BP decreased in all dipping pattern groups at Week 28, with the riser group showing the greatest change (-25.5 mmHg). A significant shift in dipping pattern and riser/non-dipper pattern changes to dipper/extreme dipper pattern were found from baseline to Week 28 (p < 0.0001). The prevalence of the riser pattern decreased from 14.4% to 9.8%, and that of the non-dipper pattern from 44.7% to 39.2%. The decrease in NT-proBNP from baseline to Week 28 was statistically significant in risers, non-dippers, dippers, and extreme dippers (p < 0.001, respectively). At baseline, the proportion of patients with NT-proBNP <55 pg/mL was lowest in risers versus the other dipping pattern types, but after reductions in NT-proBNP in all groups to Week 28, these differences disappeared. Long-term administration of esaxerenone may be a useful treatment option for nocturnal hypertension, especially in patients with a riser pattern.
Keywords: Blood pressure; Esaxerenone; Hypertension; Mineralocorticoid receptor antagonists; NT-proBNP.
© 2021. The Author(s).
Conflict of interest statement
Honoraria: KK, SI, HI, HR (Daiichi Sankyo Co., Ltd). Research funds: KK, SI, HI, HR (Daiichi Sankyo Co., Ltd). Employment: YO, SY (Daiichi Sankyo Co., Ltd).
Figures



Comment in
-
Efficacy of esaxerenone-a nonsteroidal mineralocorticoid receptor blocker-on nocturnal hypertension.Hypertens Res. 2022 Feb;45(2):376-377. doi: 10.1038/s41440-021-00803-1. Epub 2021 Nov 26. Hypertens Res. 2022. PMID: 34837032 No abstract available.
-
Esaxerenone for nocturnal hypertension and possible future direction for treatment of hypertension-cardiovascular-kidney comorbidity.Hypertens Res. 2023 Aug;46(8):2059-2061. doi: 10.1038/s41440-023-01338-3. Epub 2023 Jun 16. Hypertens Res. 2023. PMID: 37328695 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials